Searched for
NATCO PHARMA EBITDA
Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoYNatco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins an...- Buy, Sell or Hold: Nuvama maintains buy rating on Apollo Hospitals; retains Hold call on Natco PharmaBrokerages remain positive on select healthcare, pharma, and engineering services stocks, citing strong growth outlooks and solid execution.
- Natco Pharma to buy over 35% in South Africa's Adcock IngramNatco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 cr...
- NATCO Pharma shares sinks 28% in 2 days on Q3 earnings miss, brokerage downgradeNATCO Pharma shares tumbled 10% on Friday, extending a two-day slump to 28% after weak Q3 results and a target price cut by Nuvama. Profit ...
- Q3 results today: HAL, Ashok Leyland among 501 companies to announce earnings on WednesdayThe third quarter earnings season sees key companies like Ashok Leyland, Siemens, and others announcing results. Ashok Leyland is predicted...
- Hot Stocks: Brokerages on RIL, Entero Healthcare, Natco Pharma and Persistent SystemsBrokerage Nomura upheld a neutral rating on Persistent Systems, while Investec continues to advocate a buy stance on Natco Pharma and has i...
- Hold Sun Pharma and Dr Reddy's; buy Natco on dips among pharma stocks: Mayuresh JoshiMayuresh Joshi shares insights on pharma and telecom sectors, focusing on key players like Sun Pharma, Dr Reddy's, Bharti Hexacom, and Exid...
- Stock screener: MFs, FIIs drool over these 10 stocks, earn double-digit returnsInstitutional investors such as foreign portfolio investors and mutual funds have increased their stakes in at least 20 Indian stocks in th...
- Natco Pharma's comparatively reasonable valuation makes it stock pick of the weekNatco’s recent diversification of its exports to markets like Brazil, Canada, China, is doing well and is expected to do so in future as we...
- Hold Natco Pharma, target price Rs 649: Anand RathiReported profits are expected to have declined 19 per cent to Rs 982 million.
- API makers surge up to 110% in 50 days as virus hits Chinese exportsBrokerage sees coronavirus crisis as a positive for companies like Granules India and Natco.
- These 10 multibaggers are off to a flying start in 2020 after tepid 2019Caplin Point Laboratories’ 10-year return is mindboggling at 22,300 per cent. This stock has gained 23 per cent after falling 21 per cent i...
- Pharma firms likely to post soft Q3, but low base may play saviourThe USFDA granted the highest-ever approvals in a single quarter with 246 clearances.
- In search of ‘contra’ bets, investors turn to pharmaThe BSE Healthcare index was flat in 2017 compared to 28 per cent rise in Sensex.
- Pharma stocks miss rally, but this stock defies trend, zooms 60% YTD!The pharma company reported a five-fold jump in December quarter profit.
- Racing ahead on D-Street! 5 stocks with great growth potential in 2017The growth potential was determined by comparing the consensus estimates for the next 12 months with the historical 12-month value, the rep...
- Two stocks that can make you money in next 18 monhs: Avinnash GorakssakarThe company showed a very strong performance over the last 12 months. In FY16, the company posted a top line of almost Rs 1170 crore and a ...
- What to buy, sell and holdJP Morgan said Dish TV's adjusted EV/ EBITDA multiple is at 9x FY17E earnings and 7x FY18E earnings which they consider cheap.
- What to buy, sell and hold?Ambit Capital retained its sell rating on Balkrishna Industries with a target price of Rs 600 citing weak global off-highway tyre demand.
- Shares of mid-cap pharma companies surge as investors seek defensive betsInvestors lapped up shares of mid-cap pharma firms on Wednesday as weakness in the broader market prompted them to focus on these bets.
Load More
